Moderna Inc. (MRNA)
Will Moderna's Rally Continue?
Moderna (NASDAQ: MRNA) has caught the market off guard with a significant recovery in recent days – reaching current levels of approximately $27 after hitting a five-year low of $23.15 last week – following the FDA's decision to continue advising annual COVID-19 vaccinations for high-risk populations. However, this abrupt rally appears to be a singular occurrence – competitors such as Pfizer (NYSE: PFE), Sarepta Therapeutics (NASDAQ: SRPT), and CureVac (NASDAQ:CVAC) did not replicate Moderna's increase – implying the rise was primarily fueled by the FDA guidance rather than a wider sector uptrend.
Moderna Stock Looks Ripe for a Short Squeeze
Moderna Inc. NASDAQ: MRNA is down 35% in 2025, making it one of the worst-performing stocks among medical stocks and the broader market. Not surprisingly, the stock is down over 80% in the last 12 months.
MRNA, PFE Stocks Jump Despite FDA's Stricter Standards for COVID-19 Shots
Though the new FDA rules limit access to COVID-19 booster vaccines, the commitment to high-risk groups lifts Moderna, Pfizer and BioNTech stocks.
Moderna withdraws application for COVID-flu combination vaccine
Moderna said on Wednesday it had withdrawn the pending application for its flu and COVID combination vaccine candidate for adults aged 50 years and older.
Moderna shares surge as new FDA vaccine framework eases investor concerns
Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares jumped more than 6.5% on Tuesday after the US Food and Drug Administration unveiled a new framework for COVID-19 vaccine approvals that analysts said largely maintains the status quo for the company's core market. The FDA's updated guidance does not change how COVID-19 vaccines are authorized for individuals aged 65 and older or those aged six months to 64 years who are at high risk.
Top Stock Movers Now: Viking, Moderna, Uber Technologies, and More
U.S. equities were lower at midday, dragged by tech and travel stocks. The Dow Jones Industrial Average, S&P 500, and Nasdaq were all lower.
Moderna: After A Crash From $500 To $25, I'm Buying This "Call Option" On Pandemics And Cancer
Moderna's share price has collapsed from $500 to $25, but I believe the selloff is overdone, and the stock is deeply oversold. Short squeeze potential, a robust pipeline, and long-term mRNA/AI opportunities could drive a significant rebound, despite near-term losses and vaccine skepticism. Moderna's strong balance sheet, insider buying, and promising oncology candidates add to my conviction for a small, speculative position.
Why Moderna Merged Its Tech and HR Departments
The vaccine maker, which has partnered with OpenAI since 2023, is rethinking how it does workforce planning thanks to the growing capabilities of AI and other tech.
Moderna Sharpens Pipeline Focus as COVID-19 Vaccine Demand Ebbs in Q1
Moderna plans to launch 10 new marketed products over the next three years, aiming to diversify a revenue base, which is still heavily reliant on COVID-19 vaccine sales.
Moderna faces long-term threat from NIH's universal vaccine initiative, Jefferies says
Moderna Inc (NASDAQ:MRNA, ETR:0QF) could face a longer-term threat from a newly announced US government initiative to develop universal vaccines for pandemic-prone viruses, analysts at Jefferies said on Friday. The National Institutes of Health (NIH) unveiled plans this week to build a next-generation vaccine platform aimed at creating broad-spectrum, long-lasting protection against viruses like avian flu and coronaviruses.
Moderna (MRNA) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Moderna (MRNA) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Moderna: Regulatory Hurdles And Market Challenges Prompt Downgrade To Sell
Moderna's Q1 earnings reveal a significant revenue decline and high cash burn, driven by reduced demand for its COVID-19 vaccine and inventory write-downs. Regulatory setbacks for Moderna's combination flu/COVID-19 vaccine delay its market entry, adding to the company's challenges amid strong competition from other drugmakers. Despite cost-cutting efforts, Moderna's financial health is strained, with high costs and low margins, leading to a downgrade to "Sell" or "market underperform."
